Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

A dive into the deep heterogeneity of hepatocellular carcinoma.

Caruso S, Nault JC.

Gastroenterology. 2019 Oct 10. pii: S0016-5085(19)41420-0. doi: 10.1053/j.gastro.2019.10.003. [Epub ahead of print] No abstract available.

PMID:
31606468
2.

Natural history of liver adenomatosis: A long-term observational study.

Barbier L, Nault JC, Dujardin F, Scotto B, Besson M, de Muret A, Bourlier P, Zucman-Rossi J, Salamé E, Bacq Y.

J Hepatol. 2019 Aug 13. pii: S0168-8278(19)30470-2. doi: 10.1016/j.jhep.2019.08.004. [Epub ahead of print]

PMID:
31419515
3.

Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma.

Rochigneux P, Nault JC, Mallet F, Chretien AS, Barget N, Garcia AJ, Del Pozo L, Bourcier V, Blaise L, Grando-Lemaire V, N'Kontchou G, Nahon P, Seror O, Ziol M, Ganne-Carrié N, Olive D.

Oncoimmunology. 2019 May 25;8(8):1615818. doi: 10.1080/2162402X.2019.1615818. eCollection 2019.

4.

Acute pericarditis: A rare complication of gastric variceal obturation with cyanoacrylate glue.

Soualy A, Walter A, Sutter O, Nault JC.

Clin Res Hepatol Gastroenterol. 2019 Aug 7. pii: S2210-7401(19)30176-7. doi: 10.1016/j.clinre.2019.06.016. [Epub ahead of print]

PMID:
31401042
5.

Adeno-associated virus in the liver: natural history and consequences in tumour development.

La Bella T, Imbeaud S, Peneau C, Mami I, Datta S, Bayard Q, Caruso S, Hirsch TZ, Calderaro J, Morcrette G, Guettier C, Paradis V, Amaddeo G, Laurent A, Possenti L, Chiche L, Bioulac-Sage P, Blanc JF, Letouze E, Nault JC, Zucman-Rossi J.

Gut. 2019 Aug 2. pii: gutjnl-2019-318281. doi: 10.1136/gutjnl-2019-318281. [Epub ahead of print]

PMID:
31375600
6.

ESM1 as a Marker of Macrotrabecular-Massive Hepatocellular Carcinoma.

Calderaro J, Meunier L, Nguyen CT, Boubaya M, Caruso S, Luciani A, Amaddeo G, Regnault H, Nault JC, Cohen J, Oberti F, Michalak S, Bouattour M, Vilgrain V, Pageaux GP, Ramos J, Barget N, Guiu B, Paradis V, Aubé C, Laurent A, Pawlotsky JM, Ganne-Carrié N, Zucman-Rossi J, Seror O, Ziol M.

Clin Cancer Res. 2019 Oct 1;25(19):5859-5865. doi: 10.1158/1078-0432.CCR-19-0859. Epub 2019 Jul 29.

PMID:
31358545
7.

Late onset of nivolumab-induced severe gastroduodenitis and cholangitis in a patient with stage IV melanoma.

Cǎlugǎreanu A, Rompteaux P, Bohelay G, Goldfarb L, Barrau V, Cucherousset N, Heidelberger V, Nault JC, Ziol M, Caux F, Maubec E.

Immunotherapy. 2019 Aug;11(12):1005-1013. doi: 10.2217/imt-2019-0077. Epub 2019 Jul 15.

PMID:
31304833
8.

The role of telomeres and telomerase in cirrhosis and liver cancer.

Nault JC, Ningarhari M, Rebouissou S, Zucman-Rossi J.

Nat Rev Gastroenterol Hepatol. 2019 Sep;16(9):544-558. doi: 10.1038/s41575-019-0165-3. Epub 2019 Jun 28. Review.

PMID:
31253940
9.

Transient elastography predicts survival after radiofrequency ablation of hepatocellular carcinoma developing on cirrhosis.

Rekik S, Allaire M, Mumana A, Guyot E, Nkontchou G, Grando V, Blaise L, Ziol M, Nahon P, Ganne-Carrié N, Sutter O, Seror O, Nault JC.

J Gastroenterol Hepatol. 2019 Jun 24. doi: 10.1111/jgh.14763. [Epub ahead of print]

PMID:
31237018
10.

Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma.

Nault JC, Martin Y, Caruso S, Hirsch TZ, Bayard Q, Calderaro J, Charpy C, Copie-Bergman C, Ziol M, Bioulac-Sage P, Couchy G, Blanc JF, Nahon P, Amaddeo G, Ganne-Carrie N, Morcrette G, Chiche L, Duvoux C, Faivre S, Laurent A, Imbeaud S, Rebouissou S, Llovet JM, Seror O, Letouzé E, Zucman-Rossi J.

Hepatology. 2019 Jun 17. doi: 10.1002/hep.30811. [Epub ahead of print]

PMID:
31206197
11.

Multibipolar Radiofrequency Ablation for the Treatment of Mass-Forming and Infiltrative Hepatocellular Carcinomas > 5 cm: Long-Term Results.

N'Kontchou G, Nault JC, Sutter O, Bourcier V, Coderc E, Grando V, Nahon P, Ganne-Carrié N, Diallo A, Sellier N, Seror O.

Liver Cancer. 2019 May;8(3):172-185. doi: 10.1159/000489319. Epub 2018 Jun 28.

12.

RSPO2 abnormal transcripts result from read-through in liver tumours with high ß-catenin activation and CTNNB1 mutations.

Bayard Q, Nault JC, Zucman-Rossi J.

Gut. 2019 Jun 1. pii: gutjnl-2019-319089. doi: 10.1136/gutjnl-2019-319089. [Epub ahead of print] No abstract available.

PMID:
31154392
13.

Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response.

Caruso S, Calatayud AL, Pilet J, La Bella T, Rekik S, Imbeaud S, Letouzé E, Meunier L, Bayard Q, Rohr-Udilova N, Péneau C, Grasl-Kraupp B, de Koning L, Ouine B, Bioulac-Sage P, Couchy G, Calderaro J, Nault JC, Zucman-Rossi J, Rebouissou S.

Gastroenterology. 2019 Sep;157(3):760-776. doi: 10.1053/j.gastro.2019.05.001. Epub 2019 May 4.

PMID:
31063779
14.

Mutational Processes in Hepatocellular Carcinoma: The Story of Aristolochic Acid.

Nault JC, Letouzé E.

Semin Liver Dis. 2019 Jul;39(3):334-340. doi: 10.1055/s-0039-1685516. Epub 2019 Apr 30.

PMID:
31041788
15.

Can We Move on From the Discussion of Direct Antiviral Agents and Risk of Hepatocellular Carcinoma Recurrence?

Nault JC, Nahon P.

Gastroenterology. 2019 May;156(6):1558-1560. doi: 10.1053/j.gastro.2019.03.027. Epub 2019 Mar 26. No abstract available.

PMID:
30926345
16.

A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease.

Yang J, Trépo E, Nahon P, Cao Q, Moreno C, Letouzé E, Imbeaud S, Bayard Q, Gustot T, Deviere J, Bioulac-Sage P, Calderaro J, Ganne-Carrié N, Laurent A, Blanc JF, Guyot E, Sutton A, Ziol M, Zucman-Rossi J, Nault JC.

Hepatology. 2019 Jul;70(1):231-240. doi: 10.1002/hep.30623. Epub 2019 Apr 25.

PMID:
30908678
17.

Cabozantinib and the moving field of systemic treatments in advanced hepatocellular carcinoma.

Allaire M, Nault JC.

Hepatobiliary Surg Nutr. 2019 Feb;8(1):53-55. doi: 10.21037/hbsn.2018.10.12. No abstract available.

18.

Benign liver tumors

Blaise L, Sutter O, Ziol M, Nault JC.

Rev Prat. 2018 Dec;68(10):1119-1124. French.

PMID:
30869222
19.

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E.

Ann Oncol. 2019 May 1;30(5):871-873. doi: 10.1093/annonc/mdy510. No abstract available.

PMID:
30715202
20.

Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress.

Bayard Q, Meunier L, Peneau C, Renault V, Shinde J, Nault JC, Mami I, Couchy G, Amaddeo G, Tubacher E, Bacq D, Meyer V, La Bella T, Debaillon-Vesque A, Bioulac-Sage P, Seror O, Blanc JF, Calderaro J, Deleuze JF, Imbeaud S, Zucman-Rossi J, Letouzé E.

Nat Commun. 2018 Dec 7;9(1):5235. doi: 10.1038/s41467-018-07552-9.

21.

Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.

Dhanasekaran R, Nault JC, Roberts LR, Zucman-Rossi J.

Gastroenterology. 2019 Jan;156(2):492-509. doi: 10.1053/j.gastro.2018.11.001. Epub 2018 Nov 4. Review.

PMID:
30404026
22.

Molecular classification of hepatocellular adenomas: impact on clinical practice.

Védie AL, Sutter O, Ziol M, Nault JC.

Hepat Oncol. 2018 Apr 9;5(1):HEP04. doi: 10.2217/hep-2017-0023. eCollection 2018 Jan. Review.

23.

PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases.

Yang J, Trépo E, Nahon P, Cao Q, Moreno C, Letouzé E, Imbeaud S, Gustot T, Deviere J, Debette S, Amouyel P, Bioulac-Sage P, Calderaro J, Ganne-Carrié N, Laurent A, Blanc JF, Guyot E, Sutton A, Ziol M, Zucman-Rossi J, Nault JC.

Int J Cancer. 2019 Feb 1;144(3):533-544. doi: 10.1002/ijc.31910. Epub 2018 Nov 9.

PMID:
30289982
24.

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Vogel A, Cervantes A, Chau I, Daniele B, Llovet J, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255. doi: 10.1093/annonc/mdy308. No abstract available.

PMID:
30285213
25.

Systemic AA Amyloidosis Caused by Inflammatory Hepatocellular Adenoma.

Calderaro J, Letouzé E, Bayard Q, Boulai A, Renault V, Deleuze JF, Bestard O, Franco D, Zafrani ES, Nault JC, Moutschen M, Zucman-Rossi J.

N Engl J Med. 2018 Sep 20;379(12):1178-1180. doi: 10.1056/NEJMc1805673. No abstract available.

PMID:
30231230
26.

Percutaneous ablation for HCC eligible to transplantation: providing more opportunities of remission in the context of graft shortage.

Nault JC, Nahon P, Séror O.

Hepatobiliary Surg Nutr. 2018 Aug;7(4):302-304. doi: 10.21037/hbsn.2018.06.01. No abstract available.

27.

Virologic control and severity of liver disease determine survival after radiofrequency ablation of hepatocellular carcinoma on cirrhosis.

Allaire M, Rekik S, Layese R, Mumana A, Guyot E, Nkontchou G, Bourcier V, Grando V, Ziol M, Nahon P, Ganne-Carrié N, Sutter O, Audureau E, Seror O, Nault JC.

Dig Liver Dis. 2019 Jan;51(1):86-94. doi: 10.1016/j.dld.2018.07.014. Epub 2018 Jul 24.

PMID:
30126822
28.

The clinical implications of G1-G6 transcriptomic signature and 5-gene score in Korean patients with hepatocellular carcinoma.

Ahn SM, Haq F, Park I, Nault JC, Zucman-Rossi J, Yu E.

BMC Cancer. 2018 May 18;18(1):571. doi: 10.1186/s12885-018-4192-1.

29.

Reply to: "Response to: Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma".

Chalaye J, Costentin CE, Luciani A, Nault JC.

J Hepatol. 2018 Aug;69(2):555-556. doi: 10.1016/j.jhep.2018.04.020. Epub 2018 Apr 30. No abstract available.

PMID:
29719212
30.

Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas.

Nault JC, Couchy G, Caruso S, Meunier L, Caruana L, Letouzé E, Rebouissou S, Paradis V, Calderaro J, Zucman-Rossi J.

Hepatology. 2018 Sep;68(3):964-976. doi: 10.1002/hep.29884. Epub 2018 Jun 6.

PMID:
29572896
31.

Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma.

Chalaye J, Costentin CE, Luciani A, Amaddeo G, Ganne-Carrié N, Baranes L, Allaire M, Calderaro J, Azoulay D, Nahon P, Seror O, Mallat A, Soussan M, Duvoux C, Itti E, Nault JC.

J Hepatol. 2018 Aug;69(2):336-344. doi: 10.1016/j.jhep.2018.02.018. Epub 2018 Mar 6.

PMID:
29518452
32.

The role of molecular enrichment on future therapies in hepatocellular carcinoma.

Nault JC, Galle PR, Marquardt JU.

J Hepatol. 2018 Jul;69(1):237-247. doi: 10.1016/j.jhep.2018.02.016. Epub 2018 Mar 2. Review.

PMID:
29505843
33.

Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance.

Ziol M, Poté N, Amaddeo G, Laurent A, Nault JC, Oberti F, Costentin C, Michalak S, Bouattour M, Francoz C, Pageaux GP, Ramos J, Decaens T, Luciani A, Guiu B, Vilgrain V, Aubé C, Derman J, Charpy C, Zucman-Rossi J, Barget N, Seror O, Ganne-Carrié N, Paradis V, Calderaro J.

Hepatology. 2018 Jul;68(1):103-112. doi: 10.1002/hep.29762. Epub 2018 May 9.

PMID:
29281854
34.

Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.

Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten TF, Nault JC, Avila MA.

Gut. 2018 Feb;67(2):380-388. doi: 10.1136/gutjnl-2017-315068. Epub 2017 Nov 17. Erratum in: Gut. 2018 Mar;67(3):594.

35.

Is "Segmentectomy" a Suitable Term to Use in Patients Undergoing Hepatic Segmental 90Y Radioembolization for the Treatment of Hepatocellular Carcinoma Up to 3 cm?

Seror O, Nault JC, N'Kontchou G, Sutter O, Nahon P.

Radiology. 2017 Nov;285(2):690-691. doi: 10.1148/radiol.2017170852. No abstract available.

PMID:
29045224
36.

Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations.

Nault JC, Sutter O, Nahon P, Ganne-Carrié N, Séror O.

J Hepatol. 2018 Apr;68(4):783-797. doi: 10.1016/j.jhep.2017.10.004. Epub 2017 Oct 13. Review.

PMID:
29031662
37.

Reply.

Rebouissou S, Bioulac-Sage P, Nault JC, Calderaro J, Zucman-Rossi J.

Hepatology. 2017 Dec;66(6):2093-2094. doi: 10.1002/hep.29563. Epub 2017 Nov 6. No abstract available.

PMID:
28961324
38.

Molecular classification of hepatocellular adenoma in clinical practice.

Nault JC, Paradis V, Cherqui D, Vilgrain V, Zucman-Rossi J.

J Hepatol. 2017 Nov;67(5):1074-1083. doi: 10.1016/j.jhep.2017.07.009. Epub 2017 Jul 19. Review.

PMID:
28733222
39.

Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis.

Costentin CE, Decaens T, Laurent A, Nault JC, Paule B, Letoublon C, Luciani A, Calderaro J, Adam R, Bricault I, Amaddeo G, Cherqui D, Mallat A, Samuel D, Duvoux C, Ganne-Carrié N, Roudot-Thoraval F, Vibert E.

Liver Int. 2017 Dec;37(12):1869-1876. doi: 10.1111/liv.13491. Epub 2017 Jul 13.

PMID:
28609020
40.

Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.

Calderaro J, Couchy G, Imbeaud S, Amaddeo G, Letouzé E, Blanc JF, Laurent C, Hajji Y, Azoulay D, Bioulac-Sage P, Nault JC, Zucman-Rossi J.

J Hepatol. 2017 Oct;67(4):727-738. doi: 10.1016/j.jhep.2017.05.014. Epub 2017 May 19.

PMID:
28532995
41.

Advances in management of hepatocellular carcinoma.

Allaire M, Nault JC.

Curr Opin Oncol. 2017 Jul;29(4):288-295. doi: 10.1097/CCO.0000000000000378. Review.

PMID:
28509806
42.

Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series.

Sutter O, Calvo J, N'Kontchou G, Nault JC, Ourabia R, Nahon P, Ganne-Carrié N, Bourcier V, Zentar N, Bouhafs F, Sellier N, Diallo A, Seror O.

Radiology. 2017 Sep;284(3):877-886. doi: 10.1148/radiol.2017161413. Epub 2017 Apr 28.

PMID:
28453431
43.

Autoimmune-like chronic hepatitis induced by olmesartan.

Barge S, Ziol M, Nault JC.

Hepatology. 2017 Dec;66(6):2086-2088. doi: 10.1002/hep.29228. Epub 2017 Oct 30. No abstract available.

PMID:
28437842
44.

Constitutional and functional genetics of human alcohol-related hepatocellular carcinoma.

Nahon P, Nault JC.

Liver Int. 2017 Nov;37(11):1591-1601. doi: 10.1111/liv.13419. Epub 2017 Apr 11. Review.

PMID:
28296015
45.

Cancer Gene Discovery in Hepatocellular Carcinoma: The CRISPR/CAS9 Accelerator.

Nault JC.

Gastroenterology. 2017 Apr;152(5):941-943. doi: 10.1053/j.gastro.2017.02.031. Epub 2017 Mar 1. No abstract available.

PMID:
28259794
46.

Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro.

Rebouissou S, La Bella T, Rekik S, Imbeaud S, Calatayud AL, Rohr-Udilova N, Martin Y, Couchy G, Bioulac-Sage P, Grasl-Kraupp B, de Koning L, Ganne-Carrié N, Nault JC, Ziol M, Zucman-Rossi J.

Clin Cancer Res. 2017 Aug 1;23(15):4364-4375. doi: 10.1158/1078-0432.CCR-16-3118. Epub 2017 Feb 28.

47.

Germline and somatic DICER1 mutations in familial and sporadic liver tumors.

Caruso S, Calderaro J, Letouzé E, Nault JC, Couchy G, Boulai A, Luciani A, Zafrani ES, Bioulac-Sage P, Seror O, Imbeaud S, Zucman-Rossi J.

J Hepatol. 2017 Apr;66(4):734-742. doi: 10.1016/j.jhep.2016.12.010. Epub 2016 Dec 22.

PMID:
28012864
48.

Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.

Nault JC, Couchy G, Balabaud C, Morcrette G, Caruso S, Blanc JF, Bacq Y, Calderaro J, Paradis V, Ramos J, Scoazec JY, Gnemmi V, Sturm N, Guettier C, Fabre M, Savier E, Chiche L, Labrune P, Selves J, Wendum D, Pilati C, Laurent A, De Muret A, Le Bail B, Rebouissou S, Imbeaud S; GENTHEP Investigators, Bioulac-Sage P, Letouzé E, Zucman-Rossi J.

Gastroenterology. 2017 Mar;152(4):880-894.e6. doi: 10.1053/j.gastro.2016.11.042. Epub 2016 Dec 7.

49.

The end of almost 10 years of negative RCTs in advanced hepatocellular carcinoma.

Nault JC.

Lancet. 2017 Jan 7;389(10064):4-6. doi: 10.1016/S0140-6736(16)32480-1. Epub 2016 Dec 6. No abstract available.

PMID:
27932228
50.

The transcriptomic G1-G6 signature of hepatocellular carcinoma in an Asian population: Association of G3 with microvascular invasion.

Allen JC Jr, Nault JC, Zhu G, Khor AY, Liu J, Lim TK, Zucman-Rossi J, Chow PK.

Medicine (Baltimore). 2016 Nov;95(47):e5263.

Supplemental Content

Support Center